KINNATE BIOPHARMA INC. — Operating Income by Fiscal Year
4 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/bde74e23-5fa2-4894-8fa8-651d1fa7c4bb/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2023 | $-121.2M | 2023-01-01 – 2023-12-31 | evidence 0001140361-24-016132 |
| FY 2022 | $-118.5M | 2022-01-01 – 2022-12-31 | evidence 0001140361-23-011846 |
| FY 2021 | $-90.1M | 2021-01-01 – 2021-12-31 | evidence 0001140361-22-011381 |
| FY 2020 | $-36.0M | 2020-01-01 – 2020-12-31 | evidence 0001140361-22-011381 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).